Table 2.
Pathologic and clinical outcomes among patients in our immediate prostatectomy cohort who would have met 3 criteria for active monitoring from the literature.
| Clinically localized, biopsy Gleason score ≤ 7, and no significant comorbidities (N = 3959) | T1b-T2b N0M0, biopsy Gleason score ≤ 7, and PSA ≤15 ng/ml (N = 3536) | T1c PCa (N = 2330) | |
|---|---|---|---|
| Prostatectomy Gleason Score 8–10 (%) | 4 | 4 | 3 |
| Positive Surgical Margins (%) | 19 | 18 | 16 |
| Extracapsular Extension (%) | 18 | 17 | 15 |
| Seminal Vesicle Invasion (%) | 5 | 4 | 3 |
| Lymph Node Metastasis (%) | 1 | 0.4 | 0.4 |
| Biochemical Progression (%) | |||
| >0.2 ng/ml | 14 | 11 | 8 |
| >0.4 ng/ml | 11 | 8 | 5 |
| 5-Year Progression-Free Survival Rate (%) | 84 | 88 | 89 |
| Postoperative PSA Doubling Time | |||
| <3 months (%) | 2 | 2 | 2 |
| 3– 6 months (%) | 4 | 4 | 7 |
| 6–12 months (%) | 11 | 11 | 8 |
| Metastasis (%) | 1.2 | 0.6 | 0.1 |
| 5-Year | 98 | 99 | 100 |
| Metastasis-Free Survival Rate | |||
| Deceased (%) | 6.4 | 4.3 | 2.0 |
| 5-Year Overall Survival Rate | 95 | 97 | 97 |
| PCa Death (%) | 0.9 | 0.3 | 0.1 |
| 5-Year Cancer-Specific Survival Rate (%) | 99 | 99 | 100 |
| 10-Year Cancer-Specific Survival Rate (%) | 99 | 99 | 100 |